搜索范围
I0060000
应用筛选条件
关键词:'I0060000'
显示 1-30 #N/A 49 条结果 关于 "I0060000" 范围 论文
Seok Jin Kim et al.
Annals of hematology, 94(1), 71-78 (2014-08-02)
The aim of this study was to investigate the impact of the induction treatment with SMILE (dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide) chemotherapy and consolidation with upfront autologous stem cell transplantation (ASCT) on clinical outcomes of patients with stage IV
Yuki Kojima et al.
Japanese journal of clinical oncology, 44(4), 318-323 (2014-02-22)
Acquired immunodeficiency syndrome-related non-Hodgkin lymphoma is treated similarly to non-acquired immunodeficiency syndrome lymphoma, but it is not clear whether highly intensive regimens are beneficial for acquired immunodeficiency syndrome-related Burkitt lymphoma. We conducted a multicenter retrospective survey to clarify the clinical
Malcolm Lawson et al.
Scandinavian journal of urology and nephrology, 42(4), 309-317 (2008-09-11)
Cyclophosphamide and ifosfamide are commonly used cytotoxic medications that are indicated in a wide range of conditions, both benign and malignant. Complications of their use include well-recognized acute and chronic urological side-effects. Haemorrhagic cystitis, nephrotoxicity and transitional cell carcinoma can
Konrad Misiura
Mini reviews in medicinal chemistry, 6(4), 395-400 (2006-04-15)
Ifosfamide (IFO), an oxazaphosphorine-type anticancer alkylating agent, was found to be particularly useful in the treatment of a wide variety of neoplasm in adults and children. IFO is a positional isomer of cyclophosphamide (CPA) and was introduced into clinical practice
Mikko Siurala et al.
International journal of cancer, 136(4), 945-954 (2014-07-01)
Despite originating from several different tissues, soft-tissue sarcomas (STS) are often grouped together as they share mesenchymal origin and treatment guidelines. Also, with some exceptions, a common denominator is that when the tumor cannot be cured with surgery, the efficacy
Reticulated hyperpigmentation following chemotherapy for radiation-induced osteosarcoma.
Catherine A Necessary et al.
Journal of the American Academy of Dermatology, 71(1), e23-e24 (2014-06-21)
Diagnosis of brainstem involvement in NK/T cell lymphoma.
Jason C C So et al.
Annals of hematology, 93(8), 1433-1434 (2013-12-03)
A Korkmaz et al.
Cell biology and toxicology, 23(5), 303-312 (2007-01-17)
Cyclophosphamide (CP) and ifosfamide (IF) are widely used antineoplastic agents, but their side-effect of hemorrhagic cystitis (HC) is still encountered as an important problem. Acrolein is the main molecule responsible of this side-effect and mesna (2-mercaptoethane sulfonate) is the commonly
Masahiro Kurobe et al.
Journal of cancer research and clinical oncology, 141(1), 127-133 (2014-07-27)
The purpose of the study was to assess the efficacy of TIP as salvage chemotherapy for germ cell tumor (GCT) patients with relapsed disease or cisplatin (CDDP)-refractory disease and consolidation chemotherapy for patients who responded unfavorably to first-line chemotherapy. Forty-three
Ying Jin et al.
Clinical therapeutics, 36(12), 1980-1990 (2014-09-27)
The benefit of docetaxel-based therapy in the second-line treatment of advanced non-small cell lung cancer (NSCLC) is still unclear. The goal of this meta-analysis was to assess the efficacy and toxicity of docetaxel-based doublet compared with docetaxel alone for patients
Gianni Bisogno et al.
Pediatric blood & cancer, 61(4), 643-646 (2013-10-19)
Myoepithelial carcinoma (MC) of soft tissues is an aggressive tumor that rarely affects children, for whom no established treatment protocols exist. As part of the TREP (Tumori Rari in Età Pediatrica) project - an Italian network dedicated to children and
Juan Tamargo et al.
Drug safety, 38(2), 129-152 (2015-01-13)
Cardiovascular toxicity is a potential complication of cancer chemotherapy (CC) that increases the morbidity and mortality of cancer patients. Cardiac arrhythmias have been reported as an adverse effect of many chemotherapeutic drugs, including novel targeted therapies. The relationship between chemotherapy
Celalettin Eroglu et al.
American journal of clinical oncology, 38(1), 68-73 (2013-04-09)
To assess the outcomes of overall survival and posttransplantation survival in patients with Hodgkin lymphoma (HL) undergoing autologous stem cell transplantation (ASCT) because of the development of relapse or resistance after chemotherapy (CT) or CT plus radiotherapy (combined modality treatment
T Ajithkumar et al.
Clinical oncology (Royal College of Radiologists (Great Britain)), 19(2), 108-114 (2007-03-16)
Encephalopathy is a potentially fatal toxicity of ifosfamide. Clinical manifestations of encephalopathy range from fatigue and confusion to coma and death. Early identification of this toxicity and prompt cessation of ifosfamide are the essential elements in the management of ifosfamide
Ananth Shankar et al.
British journal of haematology, 165(4), 534-544 (2014-04-24)
The purpose of this national retrospective study was to evaluate the outcome in children with relapsed or primary refractory Hodgkin lymphoma [HL] after a primary chemotherapy alone treatment strategy. Between 2000 and 2005, 80 children with relapsed [n = 69]
Peter Anderson
Future oncology (London, England), 2(3), 333-343 (2006-06-22)
Liposomal muramyl tripeptide phosphatidyl ethanolamine (L-MTP-PE) is a synthetic biological investigational agent used for treating osteosarcoma. It has been used in both canine and human osteosarcoma to reduce pulmonary metastases, the most common pattern of treatment failure for sarcomas. L-MTP-PE
Y-L Kwong et al.
Leukemia, 28(4), 865-870 (2013-07-12)
Circulating Epstein-Barr virus (EBV) DNA is a biomarker of EBV-associated malignancies. Its significance in natural killer/T-cell lymphoma treated with the novel regimen SMILE was investigated. EBV DNA was quantified with a World Health Organization EBV standard in 910 plasma samples
Enrico Vizza et al.
Gynecologic oncology, 133(2), 180-185 (2014-03-05)
Minimally invasive surgery has been performed in locally advanced cervical cancer (LACC) without adverse effect in patient's overall prognosis and survival. The aim of this report is to evaluate the feasibility and morbidity of total robotic radical hysterectomy (TRRH) with
Renée L Mulder et al.
The Cochrane database of systematic reviews, (2)(2), CD006300-CD006300 (2010-02-19)
Alkylating agents, such as cyclophosphamide and ifosfamide, play a major role in the improved survival of children and young adults with bone and soft tissue sarcoma. However, there is still controversy as to their comparative anti-tumour efficacy and possible adverse
Yasuhiro Horita et al.
Antimicrobial agents and chemotherapy, 58(6), 3168-3176 (2014-03-26)
Predicting drug-drug interactions (DDIs) related to cytochrome P450 (CYP), such as CYP3A4 and one of the major drug transporters, P-glycoprotein (P-gp), is crucial in the development of future chemotherapeutic regimens to treat tuberculosis (TB) and TB/AIDS coinfection cases. We evaluated
Jean-Yves Blay et al.
European journal of cancer (Oxford, England : 1990), 50(6), 1137-1147 (2014-02-12)
This randomised phase III trial evaluated first-line trabectedin versus doxorubicin-based chemotherapy (DXCT) in patients with advanced/metastatic translocation-related sarcomas (TRS). Patients were randomly assigned (1:1) to receive trabectedin 1.5mg/m2 24-h intravenous (i.v.) infusion every 3 weeks (q3wk) (Arm A), or doxorubicin
High-dose chemotherapy for recurrent ovarian germ cell tumors.
Natraj Reddy Ammakkanavar et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33(2), 226-227 (2014-12-03)
Anna Raciborska et al.
Pediatric blood & cancer, 61(12), 2170-2174 (2014-08-29)
Ewing sarcoma (ES) is the second most common paediatric malignant bone tumor. Advances in multi-disciplinary care have resulted in significant improvement in cure rates over the last decades. However, the generalization of those results in countries traditionally excluded from large
Elham Amini et al.
Pediatric blood & cancer, 51(1), 137-140 (2008-03-14)
A 5-year-old male presented with spinal cord drop metastasis from a recurrent neurocytoma. Topotecan (0.5 mg/m(2)) and carboplatin (250 mg/m(2)) were administered on days 1-3 and ifosfamide (1,800 mg/m(2)) on days 1-5, every 21 days, for three cycles and resulted
Dieter Hoelzer et al.
Blood, 124(26), 3870-3879 (2014-11-02)
This largest prospective multicenter trial for adult patients with Burkitt lymphoma/leukemia aimed to prove the efficacy and feasibility of short-intensive chemotherapy combined with the anti-CD20 antibody rituximab. From 2002 to 2011, 363 patients 16 to 85 years old were recruited
Tanya M Trippett et al.
Pediatric blood & cancer, 62(1), 60-64 (2014-10-14)
We assessed the safety and efficacy of ifosfamide and vinorelbine (IV) as a less toxic and effective reinduction regimen for pediatric patients with relapsed or refractory Hodgkin Lymphoma. This multi-center Children's Oncology Group phase II pilot study enrolled patients <30
Karen I Sweiss et al.
Drug safety, 31(11), 989-996 (2008-10-09)
Encephalopathy occurs in 10-40% of patients treated with high-dose ifosfamide. Proposed risk factors for encephalopathy include hepatic or renal dysfunction, brain metastases, electrolyte imbalances and drug-drug interactions. The purpose of this retrospective cohort study and literature review was to estimate
F Lokiec
Annals of oncology : official journal of the European Society for Medical Oncology, 17 Suppl 4, iv33-iv36 (2006-05-17)
The incidence of central nervous system (CNS) recurrence in patients with lymphoma is about 5%. Nevertheless, this complication is very serious because it is almost always fatal. Its incidence is not sufficiently high to warrant the use of CNS prophylaxis
I Wilkinson-Ryan et al.
Gynecologic oncology, 134(1), 24-28 (2014-05-16)
Ccombination chemotherapy and radiation therapy is used for adjuvant treatment of stage III-IV endometrial cancer. The goal of this study was to review the treatment duration, toxicity, and survival for patients treated with concomitant chemotherapy and radiation. Women with stage
Tatyana Feldman et al.
British journal of haematology, 166(1), 77-83 (2014-03-26)
Relapsed/refractory diffuse large B-cell lymphoma (DLBCL) is associated with a poor prognosis. Outcomes are particularly poor following immunochemotherapy failure or relapse within 12 months of induction. We conducted a Phase I/II trial of lenalidomide plus RICE (rituximab, ifosfamide, carboplatin, and etoposide)
1/2